Abstract
Neurotrophic factors, and in particular the neurotrophins, restore the function of damaged neurons and prevent apoptosis in adults. The potential therapeutic property of the neurotrophins is however, complicated by the peptidergic structure of these trophic factors, which impairs their penetration into the brain parenchyma, and therefore makes their pharmaco-therapeutic properties difficult to evaluate. In this article we will focus on the neurotrophin Brain-derived neurotrophic factor (BDNF) and its receptors to address various therapeutic strategies that may overcome this problem. We will call this strategy “small molecule approach” because it relies on increasing the function of endogenous neurotrophins by pharmacological compounds that induce synthesis and release of neurotrophins in relevant brain areas or by small synthetic molecules that bind and activate specific neurotrophin receptors. The ability of small molecules to mimic BDNF has a potential therapeutic importance in preventing neuronal damage in several chronic neurodegenerative diseases including Parkinsons Disease, Alzheimers Disease, and AIDS dementia.
Keywords: Alzheimer's disease, apoptosis, BDNF, gangliosides, NGF, neurodegeneration, Parkinson's disease, Trk
CNS & Neurological Disorders - Drug Targets
Title: Targeting Neurotrophin Receptors in the Central Nervous System
Volume: 7 Issue: 1
Author(s): Italo Mocchetti, Milton Brown and Milton Brown
Affiliation:
Keywords: Alzheimer's disease, apoptosis, BDNF, gangliosides, NGF, neurodegeneration, Parkinson's disease, Trk
Abstract: Neurotrophic factors, and in particular the neurotrophins, restore the function of damaged neurons and prevent apoptosis in adults. The potential therapeutic property of the neurotrophins is however, complicated by the peptidergic structure of these trophic factors, which impairs their penetration into the brain parenchyma, and therefore makes their pharmaco-therapeutic properties difficult to evaluate. In this article we will focus on the neurotrophin Brain-derived neurotrophic factor (BDNF) and its receptors to address various therapeutic strategies that may overcome this problem. We will call this strategy “small molecule approach” because it relies on increasing the function of endogenous neurotrophins by pharmacological compounds that induce synthesis and release of neurotrophins in relevant brain areas or by small synthetic molecules that bind and activate specific neurotrophin receptors. The ability of small molecules to mimic BDNF has a potential therapeutic importance in preventing neuronal damage in several chronic neurodegenerative diseases including Parkinsons Disease, Alzheimers Disease, and AIDS dementia.
Export Options
About this article
Cite this article as:
Mocchetti Italo, Brown Milton and Brown Milton, Targeting Neurotrophin Receptors in the Central Nervous System, CNS & Neurological Disorders - Drug Targets 2008; 7 (1) . https://dx.doi.org/10.2174/187152708783885138
DOI https://dx.doi.org/10.2174/187152708783885138 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polyphenols: A Potential New Strategy for the Prevention and Treatment of Anxiety and Depression
Current Nutrition & Food Science Genomics and Pharmacogenomics of Brain Disorders
Current Pharmaceutical Biotechnology Polypeptide Models to Understand Misfolding and Amyloidogenesis and Their Relevance in Protein Design and Therapeutics
Protein & Peptide Letters Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Editorial Thematic Issue: Targeting Synaptic Dysfunction and Neural Connectivity in Neurological and Psychiatric Disorders
Current Pharmaceutical Design Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease
Current Alzheimer Research Alzheimer's Disease-Like Pathologies and Cognitive Impairments Induced by Formaldehyde in Non-Human Primates
Current Alzheimer Research Editorial (Thematic Issue: Ceramics, Nanotubes, Advanced Materials: Theoretical and Experimental Structure-Property Relationships: Part V)
Current Physical Chemistry Opinion Paper: A Cognitive-cultural Segregation and the Three Stages of Aging
Current Aging Science Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Anxiolytic-Like Effects of 7H-Benzo[e]perimidin-7-One Derivatives through Elevated Plus-Maze Test in Mice
Current Topics in Medicinal Chemistry Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Relationship between Social Cognition and Executive Functions in Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Current Cardiology Reviews Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Up-regulation of DMN Connectivity in Mild Cognitive Impairment Via Network-based Cognitive Training
Current Alzheimer Research The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Association of Platelet Activation with Vascular Cognitive Impairment: Implications in Dementia Development?
Current Vascular Pharmacology